Introduction {#S1}
============

Neutrophils constitute an essential part of the innate immune system in host defense against pathogens, as shown more than 100 years ago ([@B1], [@B2]). Circulating neutrophils are recruited in vast numbers at the sites of infection or sterile inflammation, in response to a variety of pathogen and host-derived inflammatory mediators ([@B3]). There, *via* adhesive interactions with endothelial cells, neutrophils rapidly infiltrate the site of inflammation ([@B4]). Uncontrolled inflammation in turn results in the release of newly produced neutrophils from the bone marrow, in a process termed as emergency granulopoiesis ([@B5]).

In addition to phagocytosis and degranulation, it has been recently proposed that neutrophils employ an additional strategy, in order to restrain infection: the release of NETs ([@B1], [@B2], [@B6], [@B7]).

Neutrophil extracellular traps are extracellular chromatin structures, formed upon certain inflammatory stimuli and composed of cytoplasmic, granular, and nuclear components of neutrophils ([@B1], [@B2], [@B6], [@B7]). To date, it is known that they can entrap and possibly kill pathogens. It has been shown that NETs bind bacteria ([@B6], [@B8], [@B9]) as well as fungi ([@B10]). The antimicrobial activity of NETs relies on both cytoplasmic and granular proteins as well as histones. This suggests that the intact NET structure is crucial for their antimicrobial function, enabling the increased local concentration of antimicrobial factors ([@B1], [@B2], [@B6], [@B7], [@B11]).

Besides their role in infectious disorders, studies carried out after 2008 support the role of NETs in the pathophysiology of non-infectious diseases, such as thrombosis ([@B12]--[@B16]), autoimmune diseases ([@B14], [@B17]--[@B22]), genetically driven autoinflammatory ([@B23]), and other inflammation-related diseases ([@B24]--[@B26]), metabolic disorders ([@B27], [@B28]), lung diseases ([@B29]--[@B32]), fibrosis ([@B33]), and cancer ([@B34]--[@B36]).

Herein, we seek to review current data regarding the proposed role of NETs in non-infectious human diseases. We also discuss the existing evidence supporting that these structures constitute a common mechanism of the pathophysiology of distinct diseases.

Mechanism of NET Formation {#S2}
==========================

Despite the morphological similarities of NETs released by neutrophils in response to different stimuli and under diverse conditions, it is nowadays widely accepted that there is more than one mechanism involved in NET release ([@B37]). Additionally, mitochondrial DNA also contributes in NET formation ([@B38], [@B39]), whereas, even though *in vitro* NET formation leads to cell death ([@B40]), it is reported that neutrophils that undergo NET release *in vivo* may remain active and functional, suggesting that NET formation may not necessarily be a terminal event ([@B41], [@B42]).

Activated neutrophils undergo dramatic morphological changes in order to release NETs ([@B43]--[@B47]). The nuclear and granular membranes disintegrate and elastase enters into the nucleus, followed by hypercitrullination of histones, chromatin decondensation into the cytoplasm, rupture of the plasma membrane, and extrusion of nuclear material from the cell into the extracellular space ([@B43]--[@B47]). The enzymes peptidyl arginine deiminase type IV (PAD4), neutrophil elastase (NE), and myeloperoxidase (MPO) have been implicated in the initial chromatin decondensation and in the degradation of the nuclear envelope ([@B43]--[@B47]). As a final step, extracellular DNA, histones, and granular enzymes form a network of NETs that entrap endogenous (e.g., platelets) and extrinsic (e.g., bacteria) particles and molecules (Figure [1](#F1){ref-type="fig"}A) ([@B43]--[@B47]). The negatively charged DNA acts as the backbone of the NET, interacting with other NET components through positive electrostatic charge ([@B43]--[@B47]). As it has been recently described, this scaffold is crucial for NET proteins to maintain their function ([@B6], [@B43], [@B47]), since dismantling of NET structures by DNase abolishes their antimicrobial activity ([@B6]). However, in the majority of these studies, PMA was used as a NET inducer ([@B48], [@B49]). Based on the criticism directed against the use of PMA as a NET inducer, the exact intracellular pathway that leads to NET release is still unclear ([@B50]).

![**Neutrophil extracellular trap (NET) formation and protein decoration**. Representative images taken using confocal microscopy, demonstrating **(A)** NET formation mechanism and **(B,C)** the two-step process through which the disease-related protein is externalized.](fimmu-07-00678-g001){#F1}

At the molecular level, NET formation is still poorly understood and it is not defined whether neutrophils employ a similar mechanism to release NETs under different circumstances. However, there is strong evidence that the production of reactive oxygen species (ROS), the relocation of NE and MPO into the nucleus, histone citrullination, and eventually the rupture of the plasma membrane are, sequentially, involved in NETosis ([@B43]--[@B47]).

Cell metabolism has major contribution in immune cell function ([@B51]), including neutrophil activation. Neutrophils rely mainly on glycolysis for their metabolic needs, enabling their adaptation to the highly hypoxic inflammatory sites ([@B52], [@B53]).

Moreover, there is evidence that the metabolic shift to the pentose phosphate pathway is important for NET release, due to the involvement of glucose-6-phosphate dehydrogenase in fueling NADPH oxidase-2 with NADPH, to produce an effective amount of ROS and thus induce NETs. In contrast, mitochondrial ROS release, which is NADPH-independent, is not effective in signaling for NET production ([@B54], [@B55]).

Additionally, NET formation has been shown to require, at least in certain circumstances, the activation of autophagy ([@B56]). Autophagy is an anti-apoptotic mechanism activated in response to cell stress, in order to regulate protein and organelle turnover, ensuring cell survival ([@B57]). The protein kinase mammalian target of rapamycin (mTOR) negatively regulates autophagy, involved also in NET formation ([@B58], [@B59]). We and others ([@B23], [@B24], [@B33], [@B56], [@B60]--[@B62]) have shown that blocking autophagy through PI3K signaling, either at the initial levels by using 3-methyladenine ([@B24], [@B60]--[@B62]) or at the level of autophagosomal acidification by using wortmannin or bafilomycin ([@B23], [@B33], [@B56], [@B62]), inhibits the induction of NET release. However, more mechanistic studies are needed to identify how autophagy is involved in NET release, even though mTOR signaling and ROS production have been linked to both processes ([@B7], [@B56], [@B59]).

It is suggested that autophagy is crucial for NET release in both infectious and non-infectious diseases, including sepsis, familiar Mediterranean fever (FMF), gout, and inflammatory-driven fibrosis ([@B12], [@B23], [@B56]).

Can NET Cargo Define Neutrophil Role in Disease? {#S3}
================================================

Independently of the stimulus, NETs are composed of DNA, citrullinated histone 3 (cit-H3), NE, and MPO, the three main proteins commonly used for their detection ([@B43]--[@B45], [@B47]). Even though a proteomic analysis of infiltrating neutrophils in diverse tissues and in different disorders could be the proof of concept, there is evidence proposing that neutrophils express and release in the form of NETs a variety of proteins, depending on the specific inflammatory environment ([@B63]). For example, tissue factor (TF) was detected on NETs in vein and arterial thrombosis ([@B16], [@B64], [@B65]), interleukin 1 beta (IL-1β) in gouty arthritis ([@B24]) and FMF ([@B23]), interleukin 17 (IL-17) in psoriasis ([@B66]) and pulmonary fibrosis ([@B33]), antimicrobial peptide LL-37 in systemic lupus erythematosus (SLE) ([@B19]), and PAD4 in rheumatoid arthritis (RA) ([@B67]).

Even though NETs constitute a common event in distinct pathophysiologic conditions, the expression of distinct bioactive proteins on NETs in different disorders might be the one that determines their specific function in disease pathogenesis.

A two-"hit" process has been proposed to explain the differential protein cargo of NETs in distinct disorders. The first "hit" in this process is the disease-specific environment that primes neutrophils to express disease-associated protein. A second "hit" is then required for the induction of NET formation (Figures [1](#F1){ref-type="fig"}B,C). However, this is a simplified model, and we cannot exclude the possibility that the same stimulus can drive both events. A typical paradigm of this two-"hit" model has been described in ST-segment elevation acute myocardial infarction ([@B16]). It has been shown in acute coronary syndromes that a variety of inflammatory stimuli trigger the cytoplasmic expression of TF in circulating neutrophils. At sites of atherosclerotic plaque rupture, locally activated platelets interact with TF-loaded neutrophils leading to the release of TF-bearing NETs inside the affected artery. The release of functional TF on NETs is able to further induce thrombin generation and platelet activation, creating a possible vicious cycle, that leads to thrombus propagation and stability ([@B16]).

The expression of these "disease-related" proteins on NETs could increase their local bioactivity ([@B12], [@B14], [@B16], [@B23], [@B66], [@B68]). On the other hand, it has been shown that, at high densities, NETs limit inflammation by degrading cytokines and chemokines ([@B69]). This balance between the pro-inflammatory and prothrombotic role of NETs, though the expression of cytokines like IL-1β and IL-17, and their anti-inflammatory role, could be exploited for the development of new therapeutic approaches.

In the following section, we review the clinical and experimental data that link NETs with pathogenesis of several disorders. Even though the list of diseases in which NETs have been identified is extensive, we believe that the further characterization of the degree of NET involvement in such disorders could enable the classification of diseases in which NETs have a definite and strong involvement under the term of "NET-driven disorders" or "NETopathies." The term NETopathy(ies) is derived from the abbreviation NET and the Greek word πάθος = *pathos*, which means disorder.

NETs in Thromboinflammation {#S3-1}
---------------------------

The widely accepted cross talk between inflammation and thrombosis has led to the introduction of the term thromboinflammation ([@B68]). Cells of the hematopoietic system, including neutrophils, platelets, and monocytes, have a major role in this process ([@B64]). There is increasing evidence implicating NET release with the development of both vein and arterial thrombosis ([@B12], [@B14], [@B16], [@B26], [@B65], [@B70]--[@B77]). Extracellular deposition of DNA co-localized with neutrophil granule proteins has been shown in thrombi from patients with deep vein thrombosis (DVT) ([@B78]), especially at the phase of organization of the thrombus ([@B70]). Additionally, circulating extracellular DNA in the form of nucleosomes and DNA associated with neutrophil granule proteins, supporting the induction of NET release, has been identified in blood samples from patients with DVT ([@B79], [@B80]). Similarly, NETs have been identified in thrombus specimens from patients undergoing thrombectomy in the context of myocardial infarction ([@B15], [@B16], [@B62], [@B71]). In a recent multicenter study in patients presenting with stent thrombosis, neutrophils were the more abundant leukocyte population in thrombus specimens, whereas NETs were identified in 23% of thrombi ([@B71]). Regarding specific disorders associated with thrombotic manifestations, NETs in thrombus specimens and/or increased levels of nucleosomes have been identified in disseminated intravascular coagulation in sepsis ([@B73]), in paroxysmal nocturnal hemoglobinuria ([@B81]), thrombotic microangiopathies ([@B82]), antiphospholipid syndrome (APS) ([@B74]), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) ([@B14]), or hemodialysis-related thrombogenicity ([@B83]). These clinical data support a role for NETs in the development of both arterial and venous thrombosis.

The prothrombotic role of NETs was further confirmed in several experimental animal models. NETs were observed in thrombi, in a baboon model ([@B75]) and in several mouse models of DVT ([@B64], [@B76], [@B84]). In a mouse model of DVT, infusion of DNase I resulted in protection from thrombosis ([@B76]), whereas PAD4^−/−^ mice were protected from thrombosis ([@B85]), supporting the pathogenetic role of NETs in venous thrombosis, at least in this animal model. The *in vivo* role of NETs in the development of thrombosis was further shown in a mouse model of APS ([@B86]). Additionally, NETs contribute in cancer-induced venous thrombosis, as shown in a mouse model of chronic myelogenous leukemia ([@B34]) and in the RIP1-Tag2 model of insulinoma and MMTV-PyMT model of breast cancer ([@B77]). Brill et al. linked histones with the prothrombotic effect of NETs, since histone infusion also resulted in thrombosis. However, there is evidence that NETs participate in DVT *via* interaction with von Willebrand factor, a factor that potentially activates platelets ([@B76]). Furthermore, it has been reported that in a mouse model of DVT TF triggers intraluminal fibrin formation, while the release of NETs activates factor XII, consolidating DVT ([@B64]). The involvement of NET-bound TF, which is the main *in vivo* initiator of coagulation ([@B87]), in NET-dependent thromboinflammation has been shown in several studies, since TF has been identified in NETs released in neutrophils from patients with sepsis, APS, AAV, or myocardial infarction ([@B12], [@B14], [@B16], [@B74]) or in a mouse model of DVT ([@B64]).

The interplay between neutrophils and platelets has been shown to have a major contribution in NET release ([@B16], [@B62], [@B72], [@B84], [@B88]). Clark et al. have shown that upon toll-like receptor 4 (TLR4) activation platelets induce the formation of NETs in a mouse model of sepsis ([@B72]). This leads not only to bacterial but also to platelet entrapment in NETs, resulting in tissue damage ([@B72]). Several studies have further identified platelet derived high mobility group box 1 (HMGB1) as the factor that mediates platelet--neutrophil interaction and NET release ([@B62], [@B84]). HMGB1 released by platelets has been shown to promote thrombosis in a mouse model of DVT ([@B84]), whereas it mediates neutrophil activation in the context of myocardial infarction ([@B62]). The importance of platelet--neutrophil interaction is prominent in coronary artery thrombosis, since it was proved that coronary thrombi are mainly composed of interacting neutrophils and platelets ([@B16], [@B62]). The rupture of the atherosclerotic plaque primes a cascade of events, which results in platelet activation and NET release, leading to thrombus formation and blood vessel occlusion. The expression of TF on NETs may propagate the further activation of the coagulation system, leading to thrombus expansion ([@B16]).

Taken together, there is strong evidence, derived by clinical and experimental observation, that neutrophils and NETs are major players in both venous and arterial thrombosis. The development and clinical use of factors that target NETs could provide, however, the definite proof for the role of NETs in thrombotic disorders.

NETs in Autoimmune Diseases {#S3-2}
---------------------------

A growing number of studies demonstrate that NETs play a driving role in the pathogenesis of a variety of autoimmune disorders, such as SLE, AAV, RA, and psoriasis. In the aforementioned disorders, NETs are a main source of autoantigens, are present in excess amount, or are decorated with disease-specific proteins.

### Systemic Lupus Erythematosus {#S3-2-1}

Systemic lupus erythematosus is a systemic autoimmune disease and a well-studied model. SLE is characterized by systemic production of autoantibodies against a plethora of intracellular and extracellular targets. These autoantibodies are able to cause extensive tissue damage ([@B89], [@B90]).

There is evidence supporting the involvement of NETs in the pathophysiology of SLE. It has been shown that NETs are directly associated with the severity and the progression of the disease ([@B91]--[@B95]). Neutrophils from SLE patients are primed to undergo NET release ([@B17], [@B96]). Autoantibodies and more specifically antibodies against LL-37 have been shown to activate neutrophils for NET release ([@B18], [@B19]). On the other hand, NETs are composed of DNA, histones, and proteins-like LL-37, providing a possible source of autoantigens for the development of lupus-specific autoantibodies (Figure [2](#F2){ref-type="fig"}B) ([@B17]--[@B19], [@B97]--[@B99]). Interestingly, Villanueva et al. reported a neutrophil subpopulation in SLE, termed as low-density granulocytes (LDG), prone to release NETs, which promote vascular damage ([@B18], [@B91], [@B100]). It was further demonstrated that LL-37-bearing NETs fuel the immune response in SLE by activating plasmacytoid dendritic cells (pDCs) in an Immunoglobulin-Fc region receptor II-a (FcRIIa) and TLR9-dependent manner. This leads to interferon alpha (IFNα) production, which is a critical player in the pathogenesis of SLE. Furthermore, IFNα triggers NET generation and activates T and B cells leading to the production of antibodies against NETs, creating a vicious cycle ([@B19], [@B97], [@B101], [@B102]).

![**NETopathies are ruled by the bioactive disease-related neutrophil extracellular trap (NET) proteins**. The clinical manifestations of **(A)** thrombosis, **(B)** systemic lupus erythematosus, **(C)** rheumatoid athritis (RA), **(D)** pulmonary fibrosis and psoriasis, **(E)** familiar Mediterranean fever are determined by the NET-mediated exposure of bioactive disease-related proteins.](fimmu-07-00678-g002){#F2}

Interestingly, there is a disease-associated defect in the clearance of NETs, due to the reduced activity of DNase I and the increased amounts of DNase I inhibitors ([@B17], [@B20], [@B94], [@B103]--[@B106]), supporting the hypothesis that dysregulation of NET clearance may be one of the initial steps that lead to lupus-specific autoantibody production.

### ANCA-Associated Vasculitis {#S3-2-2}

Antineutrophil cytoplasmic antibody-associated vasculitis is described as a group of autoimmune diseases, characterized by the presence of autoantibodies against the neutrophil granule proteins, such as proteinase 3 (PR3) and MPO. The study by Kessenbrock et al. provided the initial evidence for the link between NETs and AAV. In this study, the intraglomerular deposition of NETs in biopsies from patients with small-vessel vasculitis was shown. Additionally, it was shown that neutrophils release NETs when activated with ANCA ([@B107]). Further studies confirmed the deposition of NETs in affected tissues from patients with AAV ([@B14], [@B61], [@B108]--[@B110]), whereas increased levels of circulating NET remnants were observed in patients with AAV ([@B14], [@B22]). Additionally, a recent study correlated AAV disease activity with the presence of NET-prone LDGs in peripheral blood ([@B110]). NETs were further associated with the AAV hypercoagulability, since NETs released during active disease are loaded with TF \[Figure [2](#F2){ref-type="fig"}A ([@B14], [@B111])\].

Since PR3 and MPO are abundantly present in NETs, it has been proposed that NETs mediate the extracellular exposure of these potential autoantigens, having an important role in the initiation of the disease ([@B17], [@B20], [@B21], [@B107]). Sangaletti et al. have shown that myeloid DCs can acquire neutrophil proteins released in the form of NETs. Furthermore, immunization of mice with DCs co-cultured with NET remnants resulted in the development of MPO-ANCA and renal vasculitis ([@B112]). A common characteristic between SLE and AAV is the decreased degradation of NETs, attributed to the reduced activity and inhibition of DNase I, as well as to the protection over NETs by autoantibodies and components of the complement ([@B17], [@B20], [@B107]).

### RA and Psoriasis {#S3-2-3}

Rheumatoid arthritis is a chronic autoimmune disease that affects synovial joints. It is known that neutrophils are the most abundant cell type of synovial fluid in RA patients ([@B113]).

Recent studies identified the presence of NETs in the circulation and the release of NETs by synovial neutrophils ([@B114], [@B115]). Khandpur et al. have shown that TNF, IL-17, and anti-citrullinated protein antibodies (ACPA) promote NET release by neutrophils from patients with RA, whereas therapeutic blockade of TNF function has been shown to decrease the extensive NET generation that characterizes RA patients. Of interest, IL-17 was able to promote NET release only in neutrophils from patients with RA, which implies that the disease-specific inflammatory microenvironment primes neutrophils for NET formation ([@B115]).

Recent studies highlight that citrullinated histones in NETs consist autoantigens that stimulate and participate in the outset of the excessive inflammation, and more specifically in ACPA immune response, in RA ([@B18], [@B115]). It has been further demonstrated that RA-driven NETs are decorated with enzymatically active PAD4, which possibly further citrullinates targets, rendering them autoantigens (Figure [2](#F2){ref-type="fig"}C) ([@B49], [@B67], [@B116]). Finally, NETs in RA indirectly participate in the stimulation of distinct cell types, such as fibroblast-like synoviocytes, which invade and damage cartilage in RA ([@B115], [@B117]).

The possible involvement of NETs in the pathogenesis of psoriasis has been also proposed. Psoriasis is an autoimmune skin disorder characterized by epidermal hyperplasia and neutrophil infiltration in the epidermis. Neutrophils are involved in the pathophysiology of psoriasis, linking innate and adaptive immune system, and acting as a main source of IL-17 ([@B66], [@B118], [@B119]).

Interleukin 17 has a significant role in the pathophysiology of psoriasis causing keratinocyte hyperplasia ([@B119], [@B120]), whereas therapeutic administration of antibodies against IL-17 is efficacious in the treatment for psoriasis ([@B121]--[@B123]). The externalization of IL-17 in a bioactive form is feasible through NET formation (Figure [2](#F2){ref-type="fig"}D) ([@B66], [@B124]), which has been also observed in models of RA ([@B115]) and pancreatitis ([@B125]). The fact that the active form of IL-17 lies on NETs renders it an easily accessible target.

Taken together, a significant amount of evidence suggests that NETs contribute in the pathogenesis of several autoimmune disorders, acting either at the initiation of disease, providing a source of autoantigens, or promoting tissue injury ([@B66], [@B90], [@B93], [@B107], [@B109], [@B115]). There are reports suggesting that NETs can activate other inflammatory cell populations and promote the activation of the adaptive immune system ([@B97], [@B102], [@B115]). However, whether the specific structure of NETs and the possible modification in proteins loaded on NETs have a major impact in the break of tolerance and induction of autoimmunity still remains elusive.

NETs in Autoinflammatory Diseases {#S3-3}
---------------------------------

Recent studies revealed a possible role for NETs in the inflammatory response that governs autoinflammatory syndromes, including gout and FMF.

Gout is an autoinflammatory type of arthritis caused by the intra-articular deposition of monosodium urate crystals (MSU crystals). The deposition causes inflammatory attacks due to innate immunity activation ([@B126]--[@B129]). Additionally, the chronic form of the disease is characterized by tophus formation, causing mechanical destruction of the joint ([@B130]). It has been shown that MSU crystals cause a strong induction of NETs ([@B24], [@B131]) which, in high neutrophil concentrations, ameliorates MSU crystal-induced inflammation by promoting the degradation of inflammatory cytokines and chemokines in a mouse model of MSU-induced inflammation ([@B69], [@B132]). Despite their protective role, NETs indirectly engender the destruction of the joint by easing the packing of MSU crystals and the formation of tophi ([@B69], [@B132]). However, whether NETs support the initiation of gouty inflammation in humans remains unanswered.

Familiar Mediterranean fever is a hereditary autoinflammatory disorder, characterized by inflammatory attacks and neutrophil infiltration into the affected sites ([@B23]). Moreover, it is an IL-1β-mediated disease, and this is clear due to the fact that IL-1β blockade constitutes an emerging treatment in FMF ([@B23], [@B133], [@B134]). During FMF attacks, neutrophils undergo excessive NET formation, which decreases after the inflammation dissolution ([@B23]).

During FMF attacks increased levels of circulating MPO--DNA complexes are detected, suggesting the release of NETs in the systemic circulation, whereas their levels normalize during the resolution phase of the disease ([@B23]). The detection of bioactive IL-1β in NETs released *ex vivo* by patient neutrophils or control neutrophils treated with FMF attack serum implies that neutrophils serve as critical effector cells in the amplification of inflammation in FMF (Figure [2](#F2){ref-type="fig"}E) ([@B23]).

NETs in Metabolic Disorders {#S3-4}
---------------------------

In type II diabetes (T2D), immunological changes lead to altered levels of cytokines and changes in both number and activation status of various leukocytes, including neutrophils ([@B135]). Until recently, it was thought that inflammatory responses may have a dual role in T2D, as they seem to have a causal relationship leading to resistance to insulin, while on the other hand they seem to be intensified by the hyperglycemic state, resulting in T2D complications ([@B135]).

Bearing in mind that diabetes affects neutrophil count and activity, that hyperglycemia-driven oxidative stress facilitates diabetic complications, and that neutrophils generate oxidative stress in diabetes, it was assumed that a dysregulation in NETosis may represent the link among hyperglycemia, oxidative stress, inflammation, and diabetic complications ([@B27]). In this direction, a recent study demonstrated that high glucose *in vitro* and hyperglycemia *in vivo* induce release of NETs and their products ([@B27]). Another study provided evidence that hyperglycemic conditions lead to the formation of short-lived and unstable NETs, while also prime neutrophils and constitutively activate NET formation, leading to reduced response to subsequent external stimuli ([@B136]). Thus, it was hypothesized that neutrophils primed due to hyperglycemia may not respond to further external stimulus in T2D patients, making them susceptible to infections ([@B136]). Finally, a third study demonstrates that, in T2D patients, dysregulated NET release caused by hyperglycemia is responsible for impairment of wound healing as well as for diabetic complications ([@B137]). Even though these studies support a role for NETs in T2D, it is not clear to what extent manipulation of neutrophils could ameliorate or prevent diabetic complications.

Moreover, there is evidence that neutrophils and NETs have a potential role in the pathogenesis of type I diabetes ([@B28], [@B138], [@B139]); however, their implication in the onset and/or the development of this disease has not been investigated so far.

NETs in Lung Diseases and Fibrosis {#S3-5}
----------------------------------

Neutrophil extracellular traps have been implicated in inflammatory lung diseases and inflammatory-derived fibrosis ([@B33]). Several inflammatory lung diseases are characterized by the migration and detection of neutrophils and monocytes in the airway lumen and the bronchoalveolar lavage fluid ([@B140]). NETs have been associated with inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), acute lung injury, acute respiratory distress syndrome, and asthma ([@B29], [@B30]).

Cystic fibrosis is characterized by abundant free DNA structures in airway fluids that increase the viscosity of the sputum and lead to airflow obstruction and tissue damage. Free DNA originates mainly from NETs released from neutrophils that are recruited to the area in an effort to kill the bacterial burden, but they finally contribute to the damage of lung tissue ([@B31], [@B32]). Additionally, it has been proved that NE plays an equally important role in CF, leading to tissue damage, especially in patients under treatment that are characterized by increased DNA cleavage ([@B141]). Recombinant human deoxyribonuclease (rhDNase) is an adjunctive to antibiotics treatment for patients with CF over the last two decades, showing a beneficial effect at least in a subpopulation of patients with CF ([@B142], [@B143]). Moreover, it has been reported that DNase I and histone-blocking antibodies have been used in mice against transfusion-related acute lung injury, in which NETs play a crucial role ([@B144]). Inhibition of either NE or NET release in general could be a novel future therapeutic strategy in patients with CF ([@B141], [@B145]).

There is evidence that the inflammatory microenvironment developed in chronic lung diseases including COPD and interstitial lung disease contributes either to localized or to generalized fibrosis, respectively. Specific fibrosis-related agents, such as cigarette smoke, magnesium silicate, and bleomycin, stimulate neutrophils to undergo NETosis. NETs indirectly regulate fibrosis by activating lung fibroblasts and differentiating them into myofibroblasts, through autophagy and histone hypercitrullination. Subsequently, NET remnants, such as IL-17, regulate connective tissue growth factor (CCN2) expression and collagen production by the differentiated fibroblasts and not their differentiation (Figure [2](#F2){ref-type="fig"}D). However, NET degradation significantly restricts these effects, indicating that it could be possibly used as a restraining mechanism against fibrosis ([@B33]).

NETs in Cancer {#S3-6}
--------------

In the last few years, NETs have redefined the role of neutrophils in tumor biology ([@B34]--[@B36], [@B146]--[@B150]). It is suggested that NETs may act within the primary tumor promoting tumor progression ([@B146]--[@B148]), while at remote sites they might sequester circulating cancer cells favoring metastasis ([@B35], [@B36], [@B149]). Additionally, NETs have been implicated in cancer-associated thrombosis ([@B34], [@B147]).

There is increasing evidence supporting that, in both experimental models and cancer patients, NET deposition in the tumor mass is associated with tumor progression ([@B35], [@B146], [@B150]--[@B153]). A finding that supports the implication of NETs in tumor biology is that tumor cells predispose neutrophils to undergo NETosis ([@B34], [@B146]). Moreover, in the tumor microenvironment, NETs interact with tumor cells and expose them to bioactive proteins, possibly favoring their survival through induction of proliferation and inhibition of apoptosis, as well as supporting their escape from the primary tumor ([@B148]).

Excessive NET deposition leads to a persistent inflammatory state ([@B154]--[@B156]), which in cancer probably promotes the expression of adhesion molecules ([@B157]--[@B159]). Under inflammatory conditions, when NET formation is induced, circulating tumor cells are more prone to adhere to end organ vasculature ([@B158]--[@B160]). Thus, given that the entrapment of bacteria is one of the primary roles attributed to NETs, they probably act accordingly to capture circulating tumor cells. By entrapping tumor cells and exposing them to various neutrophil-derived factors, NETs may generate a microenvironment rich in proteins and enzymes that promote tumor cell survival and progression ([@B35], [@B36], [@B149], [@B153]). Taken together, these data support a potential pro-metastatic role for NETs, involved in early adhesion, proliferation, invasion, and angiogenesis.

Neutrophil extracellular traps have also been implicated in cancer-associated thrombosis, the second most common cause of death in cancer patients ([@B34]). Recently, it was demonstrated that, through the generation of NETs, neutrophils provide a scaffold and a stimulus for platelet adhesion and thrombus formation ([@B75]). NETs were shown to promote coagulation as well ([@B68], [@B75]). Moreover, a recent study based on murine models reported that both leukemia and solid tumors produce a factor, G-CSF, that primes neutrophils to undergo NETosis and predisposes the host to thrombosis ([@B34]). In conclusion, NETs have been identified as a key player in cancer-associated thrombosis.

The biological significance of NETs in cancer remains unclear. It is hypothesized that initially they represent a reaction of the tumor environment against the growing cancer. However, NETs seem to play an adverse role in tumor growth, offering a scaffold with an array of biologically active molecules attached on it, which may promote malignant cell survival, growth, and local tumor expansion.

Therapeutic and Diagnostic/Prognostic Potential of NETs {#S4}
=======================================================

To date, clinical and experimental evidence highlight the significant role of NETs in the pathophysiology of the aforementioned diseases. Even though studies in animal models have shown the beneficial role of NET inhibition, especially in thrombosis, it is yet unknown whether NET-targeting therapies could be effective in clinic ([@B161]). NET induction or inhibition could be beneficial for patients with diseases that have been associated with restricted or excessive NET formation, respectively (Table [1](#T1){ref-type="table"}). To this end, drug repositioning offers the opportunity for the immediate use of therapeutic agents that induce or inhibit NETs, which are already used in clinic ([@B11]).

###### 

**Potential and applied therapeutic strategies targeting neutrophil extracellular traps (NETs)**.

  NET formation blockade                                        NET integrity dismantling                NET components antagonism                                                                                                                         
  ------------------------------------------------------------- ---------------------------------------- ----------------------------------- ------------------------------------------------------------- ----------------------------------------------- -------------------------------------------
  Hydroxychloroquine (*autophagy inhibition*)                   SLE (*h*) ([@B162])                      DNases (*DNA dismantling*)          Thrombosis, cystic fibrosis (*h*) ([@B64], [@B76], [@B142])   Secukinumab (*IL-17 inhibition*)                Psoriasis (*h*) ([@B121])
  N-acetylcysteine (*ROS reduction*)                            SLE (*h*) ([@B163])                      Heparin (*chromatin dismantling*)   Thrombosis (*h*) ([@B75])                                     Anakinra & Canakinumab (*IL-1*β *inhibition*)   FMF, gout (*h*) ([@B23], [@B24], [@B134])
  Sifalimumab (*IFN-*α *inhibition*)                            SLE (*h*) ([@B164])                                                                                                                                                                        
  CI-Amidine (*PAD family inhibition*)                          RA, SLE (*m*) ([@B165], [@B166])                                                                                                                                                           
  GSK199 (*PAD4 inhibition*)                                    (*m*) ([@B167])                                                                                                                                                                            
  Adalimumab (*TNF inhibition*)                                 RA, psoriasis (*h*) ([@B115], [@B168])                                                                                                                                                     
  Roflumilast (*neutrophil--platelet interaction inhibition*)   Thrombosis (*h*) ([@B169])                                                                                                                                                                 
  Eculizumab (*C5a inhibition*)                                 PNH (*h*) ([@B170])                                                                                                                                                                        

*FMF, familial Mediterranean fever; h, human model; IFN-α, interferon alpha; IL-17, interleukin 17; IL-1β, interleukin 1 beta; m, murine model; PAD4, peptidyl arginine deiminase type IV; PNH, paroxysmal nocturnal hemoglobinuria; RA, rheumatoid arthritis; ROS, reactive oxygen species; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor*.

Several drugs already used in clinical practice might affect either NET formation or integrity, or the expression of NET proteins. For instance, it is known that hydroxychloroquine (HCQ), a drug that has been used for decades in the treatment of SLE, has anti-autophagic effect ([@B162]). Since the autophagic machinery is an essential step for NETosis, the effectiveness of HCQ may be mediated through the indirect inhibition of NET formation (Table [1](#T1){ref-type="table"}; Figure [3](#F3){ref-type="fig"}A). In addition, rhDNase administration, a therapy used in patients with CF aiming to the liquefaction of mucus ([@B142]), may possibly target NET structures. DNase promotes thrombolysis *via* degradation of NETs in murine models (Table [1](#T1){ref-type="table"}; Figure [3](#F3){ref-type="fig"}B) ([@B64], [@B76]). Moreover, monoclonal antibodies are widely used against bioactive NET proteins, externalized through NET formation. In psoriasis, treatment with anti-IL-17 antibodies ([@B121]), probably targets the IL-17-decorated NETs, the main origin of bioactive IL-17 in psoriasis ([@B66]). Finally, NET-bound IL-1β may be one of the targets of anti-IL-1β therapies, such as canakinumab which targets bioactive IL-1β in FMF or gout patients (Table [1](#T1){ref-type="table"}; Figure [3](#F3){ref-type="fig"}C) ([@B134]).

![**Targeting neutrophil extracellular trap (NET) formation or integrity, or specific NET proteins, promises novel therapeutic strategies**. **(A)** Hydroxychloroquine inhibits NET formation through its anti-autophagic activity. **(B)** rhDNase and DNase I dismantle NET structures. **(C)** Anti-interleukin 17 (IL-17) and anti-interleukin 1 beta (IL-1β) antibodies blockade bioactive IL-17 and IL-1β on NETs, respectively.](fimmu-07-00678-g003){#F3}

There are a few recent studies demonstrating that NETs could also have prognostic and/or diagnostic potential, as they could represent a disease activity marker for some of the aforementioned diseases ([@B161]). Furthermore, the measurement of NET release or specific NET protein expression in blood samples and biopsies could be a useful diagnostic tool ([@B150], [@B171]). Nevertheless, further experimental data are needed to evaluate the therapeutic, prognostic, and/or diagnostic potential of NETs.

Conclusion {#S5}
==========

The identification of NETs and the characterization of their role in disease have revived the overlooked role of neutrophils in disease pathogenesis. Phagocytosis of pathogens and limitation of infection was considered the exclusive role of neutrophils. However, mechanistic studies in animal models and clinical observation dramatically altered our perception of the involvement of neutrophils in disease during the last decade. From a patrolling police force, neutrophils are considered nowadays an important player in autoimmune diseases or thrombotic disorders, which were previously thought to be exclusively mediated by adaptive immune system and platelet or endothelial cells, respectively. The characterization of the differential protein load and function of neutrophils, and subsequently of NETs, in distinct disorders can provide novel diagnostic targets and targets for therapeutic intervention. Additionally, the study on the role of NETs in modulation of tissue homeostasis, including the initiation and resolution of inflammation and the elucidation of the effect of NETs on different cell population involved in inflammatory, autoimmune, or thrombotic disorders, will increase our knowledge in the mechanisms that govern the pathogenesis of complex disorders. The clarification of the role of NETs in the pathogenesis of such disorders and the clinical use of therapeutic agents that target NETs will enable the identification of a group of disorders that could be characterized by the term NET-associated diseases or NETopathies.
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